CTNM Earnings & Financial Statements
Contineum Therapeutics, Inc. Class A Common Stock
$8.22
+$0.07(+0.92%)
46
Overall
60
Value
45
Tech
34
Quality
Market Cap
$306.24M
Volume
208.16K
52W Range
$8.60 - $17.79
Target Price
$21.83
CTNM earnings and financial statements: Contineum Therapeutics, Inc. Class A Common Stock's income statement, balance sheet and cash flow statement, annual and quarterly.
CTNM Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | - | - | $50.00M | - |
| Operating income | -$68.06M | -$50.89M | $15.90M | -$22.81M |
| EBITDA | -$57.89M | -$41.13M | $20.70M | - |
| Net income | -$60.00M | -$42.26M | $22.72M | -$20.62M |
| EPS (diluted) | $-2.17 | $-2.18 | $0.08 | $-10.81 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total assets | $276.64M | $212.85M | $130.39M | $50.64M |
| Total liabilities | $15.65M | $14.78M | $5.70M | $11.37M |
| Shareholders’ equity | $260.99M | $198.07M | $124.68M | $39.27M |
| Cash and equivalents | $75.60M | $21.94M | $15.53M | $5.57M |
| Long-term debt | $5.91M | $4.81M | $108.0K | $791.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating cash flow | -$55.31M | -$32.84M | $19.35M | -$20.12M |
| Capital expenditure | -$231.0K | -$494.0K | - | - |
| Free cash flow | -$55.54M | -$33.36M | $18.93M | -$20.24M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CTNM | $8.22 | +0.9% | 208.16K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Contineum Therapeutics, Inc. Class A Common Stock Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW